Healthcare provider profile · identity verified

Bethany Renee Canver, MD

Internal Medicine · PENNSVILLE, NJ · NPI 1255820841

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Atorvastatin Calcium	Atorvastatin Calcium	416	175
Gabapentin	Gabapentin	245	70
Omeprazole	Omeprazole	224	90
Albuterol Sulfate Hfa	Albuterol Sulfate	199	59
Amlodipine Besylate	Amlodipine Besylate	197	92
Lisinopril	Lisinopril	169	80
Metformin Hcl	Metformin Hcl	168	60
Rosuvastatin Calcium	Rosuvastatin Calcium	149	66
Metoprolol Succinate	Metoprolol Succinate	147	56
Levothyroxine Sodium	Levothyroxine Sodium	145	59
Pantoprazole Sodium	Pantoprazole Sodium	132	49
Ibuprofen	Ibuprofen	123	50
Zolpidem Tartrate	Zolpidem Tartrate	118	27
Losartan Potassium	Losartan Potassium	113	45
Tamsulosin Hcl	Tamsulosin Hcl	110	36
Trazodone Hcl	Trazodone Hcl	109	27
Oxycodone-Acetaminophen	Oxycodone Hcl/Acetaminophen	107	16
Furosemide	Furosemide	106	40
Duloxetine Hcl	Duloxetine Hcl	100	27
Hydrochlorothiazide	Hydrochlorothiazide	90	28
Jardiance	Empagliflozin	90	30
Hydroxyzine Hcl	Hydroxyzine Hcl	84	34
Sertraline Hcl	Sertraline Hcl	77	22
Oxycodone Hcl	Oxycodone Hcl	75	15
Metformin Hcl Er	Metformin Hcl	72	23
Famotidine	Famotidine	70	28
Fluticasone Propionate	Fluticasone Propionate	70	37
Levocetirizine Dihydrochloride	Levocetirizine Dihydrochloride	67	19
Lisinopril-Hydrochlorothiazide	Lisinopril/Hydrochlorothiazide	67	29
Buprenorphine-Naloxone	Buprenorphine Hcl/Naloxone Hcl	64	11
Meloxicam	Meloxicam	63	30
Naproxen	Naproxen	60	30
Alprazolam	Alprazolam	57	17
Cyclobenzaprine Hcl	Cyclobenzaprine Hcl	57	22
Ozempic	Semaglutide	57	17
Carvedilol	Carvedilol	56	22
Clonazepam	Clonazepam	54	20
Eliquis	Apixaban	54	22
Allopurinol	Allopurinol	53	14
Simvastatin	Simvastatin	52	27
Glimepiride	Glimepiride	51	20
Mirtazapine	Mirtazapine	51	15
Mounjaro	Tirzepatide	47	suppressed
Escitalopram Oxalate	Escitalopram Oxalate	41	15
Montelukast Sodium	Montelukast Sodium	41	20
Trelegy Ellipta	Fluticasone/Umeclidin/Vilanter	41	12
Buspirone Hcl	Buspirone Hcl	40	suppressed
Ventolin Hfa	Albuterol Sulfate	39	15
Venlafaxine Hcl Er	Venlafaxine Hcl	38	suppressed
Amitriptyline Hcl	Amitriptyline Hcl	36	suppressed
Aripiprazole	Aripiprazole	36	suppressed
Celecoxib	Celecoxib	36	suppressed
Trulicity	Dulaglutide	36	suppressed
Metoprolol Tartrate	Metoprolol Tartrate	35	18
Losartan-Hydrochlorothiazide	Losartan/Hydrochlorothiazide	34	15
Farxiga	Dapagliflozin Propanediol	33	suppressed
Pramipexole Dihydrochloride	Pramipexole Di-Hcl	32	suppressed
Alendronate Sodium	Alendronate Sodium	30	11
Dicyclomine Hcl	Dicyclomine Hcl	30	suppressed
Potassium Chloride	Potassium Chloride	30	15
Lantus Solostar	Insulin Glargine,hum.Rec.Anlog	29	suppressed
Clopidogrel	Clopidogrel Bisulfate	28	16
Tramadol Hcl	Tramadol Hcl	28	suppressed
Azithromycin	Azithromycin	27	25
Ezetimibe	Ezetimibe	27	suppressed
Ramipril	Ramipril	27	suppressed
Ondansetron Odt	Ondansetron	26	suppressed
Prednisone	Prednisone	26	19
Meclizine Hcl	Meclizine Hcl	25	suppressed
Xarelto	Rivaroxaban	25	suppressed
Warfarin Sodium	Warfarin Sodium	24	suppressed
Hydrocortisone	Hydrocortisone	23	suppressed
Quetiapine Fumarate	Quetiapine Fumarate	23	suppressed
Varenicline Tartrate	Varenicline Tartrate	23	12
Glipizide	Glipizide	22	suppressed
Nitrofurantoin Mono-Macro	Nitrofurantoin Monohyd/M-Cryst	22	21
Tizanidine Hcl	Tizanidine Hcl	22	11
Donepezil Hcl	Donepezil Hcl	21	suppressed
Esomeprazole Magnesium	Esomeprazole Magnesium	20	suppressed
Amoxicillin-Clavulanate Potass	Amoxicillin/Potassium Clav	19	18
Loperamide	Loperamide Hcl	19	suppressed
Sumatriptan Succinate	Sumatriptan Succinate	19	suppressed
Clonidine Hcl	Clonidine Hcl	18	suppressed
Memantine Hcl	Memantine Hcl	18	suppressed
Nano 2nd Gen Pen Needle	Pen Needle, Diabetic	18	suppressed
Valsartan	Valsartan	18	suppressed
Fenofibrate	Fenofibrate	17	suppressed
Diclofenac Sodium	Diclofenac Sodium	16	11
Fluticasone Propionate Hfa	Fluticasone Propionate	16	suppressed
Hydrocodone-Acetaminophen	Hydrocodone/Acetaminophen	16	suppressed
Naloxone Hcl	Naloxone Hcl	16	16
Nystatin	Nystatin	16	suppressed
Ondansetron Hcl	Ondansetron Hcl	16	suppressed
Paroxetine Hcl	Paroxetine Hcl	16	suppressed
Verapamil Er	Verapamil Hcl	16	suppressed
Clotrimazole-Betamethasone	Clotrimazole/Betamethasone Dip	15	suppressed
Fluticasone-Salmeterol	Fluticasone Propion/Salmeterol	15	suppressed
Oxybutynin Chloride Er	Oxybutynin Chloride	15	suppressed
Fluoxetine Hcl	Fluoxetine Hcl	14	suppressed
Lorazepam	Lorazepam	14	11
Pravastatin Sodium	Pravastatin Sodium	14	suppressed
Carbamazepine Er	Carbamazepine	13	suppressed
Januvia	Sitagliptin Phosphate	13	suppressed
Paxlovid	Nirmatrelvir/Ritonavir	13	13
Budesonide-Formoterol Fumarate	Budesonide/Formoterol Fumarate	12	suppressed
Butalbital-Acetaminophen-Caffe	Butalb/Acetaminophen/Caffeine	12	suppressed
Fenofibrate	Fenofibrate,micronized	12	suppressed
Metoclopramide Hcl	Metoclopramide Hcl	12	suppressed
Nyamyc	Nystatin	12	suppressed
Promethazine Hcl	Promethazine Hcl	12	suppressed
Bupropion Xl	Bupropion Hcl	11	suppressed
Carisoprodol	Carisoprodol	11	suppressed
Doxycycline Hyclate	Doxycycline Hyclate	11	suppressed
Incruse Ellipta	Umeclidinium Bromide	11	suppressed
Ketoconazole	Ketoconazole	11	suppressed
Prochlorperazine Maleate	Prochlorperazine Maleate	11	suppressed
Tolterodine Tartrate Er	Tolterodine Tartrate	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error